3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
44
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Motor Activity
1
Interventions
Cisplatin
1038
Cyclophosphamide
972
Carboplatin
952
Radiotherapy
890
Bevacizumab
845
Gemcitabine
817
pembrolizumab
758
Paclitaxel
738
Docetaxel
733
Oxaliplatin
704
Capecitabine
646
Fluorouracil
563
Rituximab
559
Nivolumab
506
Dexamethasone
487
Etoposide
468
Doxorubicin
458
Irinotecan
442
Drug Therapy
400
Leucovorin
376
Cytarabine
342
Cetuximab
338
Lenalidomide
326
Trastuzumab
321
Pemetrexed
314
durvalumab
295
Filgrastim
287
Magnetic Resonance Spectroscopy
277
Temozolomide
275
Prednisone
273
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
High-Intensity Interval Training
×
Clear all
NCT04593862
2024-09-19
BRAVE
University of Alberta
Phase 2
Completed
25 enrolled